Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Metastatic or Unresectable Sarcoma
NCT02500797Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2015
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in soft tissue sarcoma (STS), bone sarcoma, Liposarcoma and 2 more, sponsored by National Cancer Institute. Started Aug 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
soft tissue sarcoma (STS)bone sarcomaLiposarcomaundifferentiated pleomorphic sarcoma (UPS)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02500797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500797.